RLX Technology overseas expansion is now the central question for investors after a regulatory timing effect distorted the company’s recent revenue trajectory. The branded e-vapor company, which already draws more than 70% of its revenue from outside China, must show that Europe and newer product categories can carry growth once a one-time boost fades.
What the Latest Numbers Show
In the second quarter, RLX reported net revenues of RMB1.01 billion, about $149 million, up 14.8% year over year. International sales made up 68.5% of the total. Gross margin improved to 35.4% from 27.5%, lifting gross profit by 47.8% to RMB357.8 million. Non-GAAP operating income rose 28.8% to RMB149.6 million, the eleventh consecutive quarter of positive non-GAAP operating profit.
Those figures look solid on their own. But the first quarter was unusually strong: revenue jumped 96.2% to RMB1.59 billion because of a one-time pull-forward tied to regulatory export adjustments. That timing shift explains why second-quarter revenue declined sequentially, and it complicates any simple read of the growth rate.
Profit and Cash Flow Diverge
Non-GAAP net income fell to RMB238.8 million from RMB291.2 million a year earlier, while operating cash flow turned negative at RMB63.2 million. The gap between reported profit and cash generation matters because it shows the business is not yet converting its earnings into cash at the same pace.
For a small-cap value candidate, that distinction is important. RLX met screening criteria with a forward P/E ratio of 10.59 and trailing twelve-month revenue growth of 39.66%, but the pull-forward effect means the trailing growth figure overstates the underlying pace.
Europe and Oral Nicotine Pouches
Management is leaning on two levers to replace the pull-forward. In July, RLX acquired a 51% stake in a Western European distributor of smoke-free and consumer products, a deal expected to significantly boost reported revenue starting in the third quarter. The company has also introduced oral nicotine pouches and is building a manufacturing facility in Southeast Asia.
Those moves expand the addressable market beyond e-vapor, but they also introduce execution risk. Distributor acquisitions can lift reported sales quickly, while new categories and new plants take time to scale. The market will be watching whether the added revenue is durable rather than another timing-driven spike.
Why the Stock Screens as a Value Play
RLX appeared in a small-cap value screen that required companies to trade below 15 times forward earnings and grow trailing revenue by more than 20%. It ranked sixth on a list of small-cap value stocks and tenth among entries rated by hedge fund ownership, with 15 hedge funds holding shares in the second quarter of 2026.
The broader backdrop has made small-cap value more attractive to some investors. As AI-related stocks pulled back, market breadth improved, and value indexes outperformed growth. Royce Investment Partners’ Francis Gannon noted that the Russell 2000 Value Index fell 4.9% in the third quarter, compared with a 9.4% drop in the Russell 2000 Growth Index, and argued that accelerating earnings, attractive relative valuations and low expectations could favor small-cap investors.
Still, rotation has limits. Miller Tabak’s Matt Maley warned that a sharper decline in major averages could push investors toward cash rather than other sectors. That makes balance-sheet strength and cash generation essential for small-cap value names, not just a low forward multiple.
The Test Ahead
RLX Technology overseas expansion must now prove it can deliver organic growth beyond the regulatory pull-forward. The European distributor stake and the oral nicotine pouch launch are the clearest candidates, but the second-quarter cash outflow and the sequential revenue decline show the transition is not yet complete. Investors will need to separate reported revenue gains from underlying demand as the third quarter unfolds.
